In Brief: EndoVascular Technologies
This article was originally published in The Gray Sheet
Executive Summary
EndoVascular Technologies: Initial Phase II study results for the firm's bifurcated EGS endovascular grafting system to treat abdominal aortic aneurysm released June 2 demonstrate a 49% decrease in hospital stay with EGS use versus standard AAA surgery. Mean hospital stay was 3.9 days for the EGS group versus 7.6 days for surgical controls. The 209 patient study included 106 EGS patients and 103 surgical control patients treated at 20 U.S. sites. Results showed that for EGS patients, the prosthesis "was successfully delivered and implanted in 96 of 106 attempted procedures, representing 90.6% primary technical success," the firm states. "The 30-day mortality rate" for the EGS group patients was 1.9% versus 3.9% for the surgical control group. Serious complications were seen in 1.9% of EGS patients and 2.9% of surgical controls. Results of the firm's tube EGS system Phase II studies were reported in January ("The Gray Sheet" Jan. 20, I&W-6)...